FDA Approves Marketing of First Device to Treat ADHD

Pin It

]Source:  Medical X-Press]

(HealthDay)—Marketing has been approved for the first medical device to treat attention-deficit/hyperactivity disorder (ADHD), the U.S. Food and Drug Administration announced Friday.

The Monarch external Trigeminal Nerve Stimulation (eTNS) System is available by prescription only for patients aged 7 to 12 years old who are not currently taking prescription medication for ADHD. The FDA indicates that the Monarch eTNS System should be used in the home under caregiver supervision. The device, which is about the size of a cell phone, according to the FDA, generates a low-level electrical pulse to the trigeminal nerve from a wire to a small patch placed above the patient’s eyebrows. The patient should feel a tingling sensation.

Read the Rest of this Press Release on Medical X-Press

This entry was posted in Blog, OT, Psych and tagged , , , , . Bookmark the permalink.

Comments are closed.